Case report demonstrates successful use of secukinumab in treating generalized pustular psoriasis in a pregnant woman, highlighting its impact on pregnancy outcomes.
Secukinumab is one of the biologic drugs targeting interleukin-17 (IL-17) which is highly effective in the treatment of generalized pustular psoriasis (GPP). However, there is only limited data regarding treat-ment with GPP during pregnancy because of the rarity of the disease as well as ethical issues. This study describes the successful treatment with secukinumab of a 10 weeks pregnant women with recurrent GPP.
No takes yet. Share an insight, caveat, or question.
Koompawichit et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: